Business Context and Reporting Period
Company: Biorestorative Therapies, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: July 24, 2014
Reporting Period: Events occurring between June 24, 2014, and August 5, 2014.
Key Financial Metrics and Capital Structure Changes
This filing details unregistered sales of equity securities and debt conversions rather than standard operating financial metrics. The filing text does not provide clear values for revenue, profit, cash flow, margins, or overall liquidity.
- Cash Raised: $230,000 from the sale of 803,333 shares of common stock.
- Debt Reduction: $139,929 of outstanding indebtedness (inclusive of accrued interest) converted into 716,377 shares of common stock.
- Service Compensation: 652,040 shares of common stock issued for services rendered.
- Warrants Issued:
- 200,833 warrants (exercise price $0.75, 5-year term) issued with cash purchase.
- 510,000 warrants (exercise prices $0.75 to $1.00, 5-year term) issued for services.
Material Changes Versus Prior Period
The filing reports significant dilution events and capital structure adjustments during the reported period:
- Share Issuance: A total of 2,171,750 shares of common stock were issued across three distinct transactions (cash, debt conversion, and services).
- Debt Elimination: Approximately $140,000 in liabilities were extinguished through equity conversion.
- Warrant Liability: New potential dilution was created through the issuance of 710,833 warrants.
Guidance, Outlook, and Risks
Management Commentary: The Company relied upon Section 4(a)(2) of the Securities Act of 1933 for all issuances, asserting they were private transactions not involving a public offering. Management confirmed that no general solicitation was used and that investors were provided access to financial reports (10-K, 10-Q, 8-K) and press releases.
Risks and Contingencies:
- Dilution Risk: Significant issuance of shares and warrants may dilute existing shareholders.
- Regulatory Compliance: The Company relies on the belief that all investors are accredited; failure to meet this standard could impact the validity of the exemptions.
Outlook: The filing text does not provide specific forward-looking guidance or operational outlook.
Investor Verification Checklist
- Verify the total number of outstanding shares post-issuance to assess dilution impact.
- Confirm the current status of the $139,929 debt conversion and whether any residual interest remains.
- Review the terms of the 710,833 warrants issued to understand future dilution potential.
- Check subsequent filings for any updates on the Company's cash position following the $230,000 raise.